MX2022016536A - Tratamiento del síndrome de x frágil con cannabidiol. - Google Patents

Tratamiento del síndrome de x frágil con cannabidiol.

Info

Publication number
MX2022016536A
MX2022016536A MX2022016536A MX2022016536A MX2022016536A MX 2022016536 A MX2022016536 A MX 2022016536A MX 2022016536 A MX2022016536 A MX 2022016536A MX 2022016536 A MX2022016536 A MX 2022016536A MX 2022016536 A MX2022016536 A MX 2022016536A
Authority
MX
Mexico
Prior art keywords
fragile
syndrome
cannabidiol
treatment
symptoms
Prior art date
Application number
MX2022016536A
Other languages
English (en)
Inventor
Terri Sebree
James Griesser
Thomas W Dobbins
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of MX2022016536A publication Critical patent/MX2022016536A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente tecnología se refiere a un método para tratar uno o más síntomas del Síndrome de X Frágil de Metilación Completa (Fmet) en un sujeto que incluye administrar una cantidad efectiva de cannabidiol al sujeto de manera que se tratan uno o más síntomas del Síndrome de X Frágil.
MX2022016536A 2020-06-29 2021-06-28 Tratamiento del síndrome de x frágil con cannabidiol. MX2022016536A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063045664P 2020-06-29 2020-06-29
PCT/IB2021/055772 WO2022003541A1 (en) 2020-06-29 2021-06-28 Treatment of fragile x syndrome with cannabidiol

Publications (1)

Publication Number Publication Date
MX2022016536A true MX2022016536A (es) 2023-03-15

Family

ID=76797036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016536A MX2022016536A (es) 2020-06-29 2021-06-28 Tratamiento del síndrome de x frágil con cannabidiol.

Country Status (13)

Country Link
US (3) US20210401769A1 (es)
EP (1) EP4171528A1 (es)
JP (1) JP7830358B2 (es)
KR (1) KR20230031317A (es)
CN (2) CN121606556A (es)
AU (1) AU2021301406A1 (es)
BR (1) BR112022026044A2 (es)
CA (1) CA3183065A1 (es)
IL (1) IL299399A (es)
JO (1) JOP20220338A1 (es)
MX (1) MX2022016536A (es)
TW (1) TWI902836B (es)
WO (1) WO2022003541A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058102T2 (hu) 2017-09-28 2022-07-28 Zynerba Pharmaceuticals Inc Fragilis X szindróma és autizmus kezelése kannabidiollal
CA3122735A1 (en) 2018-12-14 2020-06-18 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
CA3235677A1 (en) * 2021-10-22 2023-04-27 Joseph Palumbo Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100273895A1 (en) 2009-04-28 2010-10-28 Alltranz Inc. Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same
TW201606304A (zh) * 2013-09-09 2016-02-16 亞克柏拉有限公司 測定治療反應之方法
GB2549277B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
EP3668500A4 (en) * 2017-08-14 2021-04-28 Zynerba Pharmaceuticals, Inc. METHOD OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GEL
HUE058102T2 (hu) * 2017-09-28 2022-07-28 Zynerba Pharmaceuticals Inc Fragilis X szindróma és autizmus kezelése kannabidiollal

Also Published As

Publication number Publication date
US20240122873A1 (en) 2024-04-18
CA3183065A1 (en) 2022-01-06
TWI902836B (zh) 2025-11-01
KR20230031317A (ko) 2023-03-07
US20260027137A1 (en) 2026-01-29
BR112022026044A2 (pt) 2023-03-07
IL299399A (en) 2023-02-01
JP2023532880A (ja) 2023-08-01
CN115812000A (zh) 2023-03-17
CN121606556A (zh) 2026-03-06
WO2022003541A1 (en) 2022-01-06
JOP20220338A1 (ar) 2023-01-30
JP7830358B2 (ja) 2026-03-16
AU2021301406A8 (en) 2023-03-30
US20210401769A1 (en) 2021-12-30
EP4171528A1 (en) 2023-05-03
TW202216127A (zh) 2022-05-01
AU2021301406A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
JOP20200082B1 (ar) علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول
MX2022016536A (es) Tratamiento del síndrome de x frágil con cannabidiol.
MX2022012576A (es) Inhibidores de axl para terapia antiviral.
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
MX2022013749A (es) Metodos y composiciones para el tratamiento del coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2).
PH12015502276B1 (en) Therapeutic uses of empagliflozin
WO2018231905A8 (en) Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
BR112012006468A2 (pt) métodos de tratamento de inflamação
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
WO2022115709A3 (en) Methods and composition for treating metabolic syndrome
WO2022119858A8 (en) Compounds for the treatment of sars
BR112015015646A2 (pt) método para tratar biologicamente água residual com biomassa e intensificar o potencial de acúmulo de poli-hidroxialcanoato (pha) da biomassa
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
MX2023006651A (es) Tratamiento de la hemofilia con fitusirán.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
BR112016011161A2 (pt) Método para processar legumes, e, produto de legume processado
JOP20220310A1 (ar) علاج اضطراب طيف التوحد بكانابيديول
WO2021211784A3 (en) Method of treating coronavirus infections
MX2022011692A (es) Tecnologias para prevenir o tratar infecciones.
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
MX2025002312A (es) Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina
MX380367B (es) Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina.